Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Gong, Hui Ping ^a   Du, Yi Meng ^a   Zhong, Li Na ^b   Dong, Zhao Qiang ^a   Wang, Xin ^a   Mao, Yong Jun ^b   Lu, Qing Hua ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL WALL THICKENING; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; BLOOD; CAROTID ARTERY; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME ASSAY; MIDDLE AGED; PATHOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; ENZYME ASSAYS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 78651488964     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-13     Document Type: Article

References (45)

1. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. SM Grundy HB Brewer Jr JI Cleeman SC Smith Jr C Lenfant American Heart Association National Heart, Lung, and Blood Institute, Circulation 2004 109 433 438 10.1161/01.CIR.0000111245.75752.C6 14744958
2. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the national health and nutrition examination survey ii mortality study. ES Ford, Atherosclerosis 2004 173 309 314 10.1016/j.atherosclerosis.2003.12.022 15064107
3. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. IJ Kullo AE Cassidy PA Peyser ST Turner PF Sheedy LF Bielak, Am J Cardiol 2004 94 1554 1558 10.1016/j.amjcard.2004.08. 038 15589016
4. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the bogalusa heart study. WS Tzou PS Douglas SR Srinivasan MG Bond R Tang W Chen GS Berenson JH Stein, J Am Coll Cardiol 2005 46 457 463 10.1016/j.jacc.2005.04.046 16053958 (Pubitemid 41040286)
5. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. K Wallenfeldt J Hulthe B Fagerberg, J Intern Med 2005 258 28 37 10.1111/j.1365-2796.2005.01511.x 15953130
6. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. KK Koh SH Han MJ Quon, J Am Coll Cardiol 2005 46 1978 1985 10.1016/j.jacc.2005.06.082 16325028
7. Atherosclerosis-an inflammatory disease. R Ross, N Engl J Med 1999 340 115 126 10.1056/NEJM199901143400207 9887164
8. Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects. M Persson B Hedblad JJ Nelson G Berglund, Arterioscler Thromb Vasc Biol 2007 27 1411 1416 10.1161/ATVBAHA.107.142679 17431184
9. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. CM Ballantyne RC Hoogeveen H Bang J Coresh AR Folsom G Heiss AR Sharrett, Circulation 2004 109 837 842 10.1161/01.CIR.0000116763.91992.F1 14757686
10. Plasma platelet activating factor-acetylhydrolase (PAF-AH). K Karasawa A Harada N Satoh K Inoue M Setaka, Prog Lipid Res 2003 42 93 114 Review. 10.1016/S0163-7827(02)00049-8 12547653
11. New Insights Into the Role of Lipoprotein(a)- Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease. S Tsimikas LD Tsironis AD Tselepis, Arterioscler Thromb Vasc Biol 2007 27 2094 2099 10.1161/01.ATV.0000280571.28102.d4 17626905
12. Lipoprotein-associated phospholipase A2. JP McConnell DM Hoefner, Clin Lab Med 2006 26 679 697 vii. Review. 10.1016/j.cll.2006.06.003 16938590
13. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. K Sudhir, J Clin Endocrinol Metab 2005 90 3100 3105 10.1210/jc.2004-2027 15713711
14. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. D Mannheim J Herrmann D Versari M Gössl FB Meyer JP McConnell LO Lerman A Lerman, Stroke 2008 39 1448 1455 10.1161/STROKEAHA.107.503193 18356547
15. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. DN Kiortsis S Tsouli ES Lourida V Xydis MI Argyropoulou M Elisaf AD Tselepis, Angiology 2005 56 451 458 10.1177/000331970505600413 16079929
16. Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. S Campo MA Sardo A Bitto A Bonaiuto G Trimarchi M Bonaiuto M Castaldo C Saitta S Cristadoro A Saitta, Clin Chem 2004 50 2077 2082 10.1373/clinchem.2004.036863 15364890 (Pubitemid 39425845)
17. Intima media thickness as a surrogate marker for generalised atherosclerosis. ML Bots DE Grobbee, Cardiovasc Drugs Ther 2002 16 341 351 10.1023/A:1021738111273 12652104
18. The metabolic syndrome-a new worldwide definition. KG Alberti P Zimmet J Shaw IDF Epidemiology Task Force Consensus Group, Lancet 2005 366 1059 1062 10.1016/S0140-6736(05)67402-8 16182882
19. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
20. A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. PS Sidhu SR Desai, Br J Radiol 1997 70 85 89 9059301
21. Obesity, Inflammation, and Insulin Resistance. SE Shoelson L Herrero A Naaz, Gastroenterology 2007 132 2169 2180 10.1053/j.gastro.2007.03.059 17498510
22. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. ML Brennan SL Hazen, Curr Opin Lipidol 2003 14 353 359 10.1097/00041433-200308000-00003 12865732
23. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. N Kume MA Gimbrone Jr, J Clin Invest 1994 93 907 911 10.1172/JCI117047 7509351
24. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. AD Tselepis M John Chapman, Atheroscler Suppl 2002 3 57 68 10.1016/S1567-5688(02)00045-4 12573364
25. The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. H Noto P Chitkara P Raskin, J Diabetes Complications 2006 20 343 348 10.1016/j.jdiacomp.2006.07.004 17070436
26. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. S Tsimikas J Willeit M Knoflach M Mayr G Egger M Notdurfter JL Witztum CJ Wiedermann Q Xu S Kiechl, Eur Heart J 2009 30 107 115 10.1093/eurheartj/ehn502 19019993
27. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. M Persson JA Nilsson JJ Nelson B Hedblad G Berglund, Atherosclerosis 2007 190 388 396 10.1016/j.atherosclerosis.2006.02.016 16530769
28. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. T Okada M Miyashita Y Kuromori F Iwata K Harada H Hattori, Arterioscler Thromb Vasc Biol 2006 26 40 41 10.1161/01.ATV.0000217284.86123.2c 16627814
29. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. JS Rana BJ Arsenault JP Després M Cté PJ Talmud E Ninio JW Jukema NJ Wareham JJ Kastelein KT Khaw SM Boekholdt, Eur Heart J 2009 19224930
30. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. MA Alpert CR Lambert H Panayiotou BE Terry MV Cohen CV Massey MW Hashimi V Mukerji, Am J Cardiol 1995 76 1194 1197 10.1016/S0002-9149(99)80338-5 7484912
31. Plasma plateletactivating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis. RV Shohet A Anwar JM Johnston JC Cohen, Am J Cardiol 1999 83 109 111 A8-9 10.1016/S0002-9149(98) 00791-7 10073795
32. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. PP Toth PA McCullough MS Wegner KJ Colley, Expert Rev Cardiovasc Ther 2010 8 425 438 10.1586/erc.10.18 20222820
33. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. T Häkkinen JS Luoma MO Hiltunen CH Macphee KJ Milliner L Patel SQ Rice DG Tew K Karkola S Ylä-Herttuala, Arterioscler Thromb Vasc Biol 1999 19 2909 2917 10591668
34. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. KC Vickers CT Maguire R Wolfert AR Burns M Reardon R Geis P Holvoet JD Morrisett, J Lipid Res 2009 50 1735 1743 10.1194/jlr.M800342-JLR200 19359705
35. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. GJ Blake N Dada JC Fox JE Manson PM Ridker, J Am Coll Cardiol 2001 38 1302 1306 10.1016/S0735-1097(01)01554-6 11691499
36. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. ES Brilakis JP McConnell RJ Lennon AA Elesber JG Meyer PB Berger, Eur Heart J 2005 26 137 144 10.1093/eurheartj/ehi010 15618069
37. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. DM Stafforini LW Tjoelker SP McCormick D Vaitkus TM McIntyre PW Gray SG Young SM Prescott, J Biol Chem 1999 274 7018 7024 10.1074/jbc.274.11.7018 10066756
38. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. R Kawamoto H Tomita Y Oka A Kodama A Kamitani, Intern Med 2005 44 1232 1238 10.2169/internalmedicine.44.1232 16415542
39. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. GM Reaven YD Chen J Jeppesen P Maheux RM Krauss, J Clin Invest 1993 92 141 146 10.1172/JCI116541 8325978
40. A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. SM Haffner L Mykkänen D Robbins R Valdez H Miettinen BV Howard MP Stern R Bowsher, Diabetologia 1995 38 1328 1336 10.1007/BF00401766 8582543
41. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. BV Howard EJ Mayer-Davis D Goff DJ Zaccaro A Laws DC Robbins MF Saad J Selby RF Hamman RM Krauss SM Haffner, Metabolism 1998 47 1174 1179 10.1016/S0026-0495(98)90319-5 9781617
42. Platelet-activating factor acetylhydrolase prevents myocardial ischemia- reperfusion injury. EN Morgan EM Boyle Jr W Yun JC Kovacich TG Canty Jr E Chi TH Pohlman ED Verrier, Circulation 1999 100 I365 II368 10567331
43. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. H Arakawa JY Qian D Baatar K Karasawa Y Asada Y Sasaguri ER Miller JL Witztum H Ueno, Circulation 2005 111 3302 3309 10.1161/CIRCULATIONAHA.104.476242 15956136
44. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. PT Wootton JW Stephens SJ Hurel H Durand J Cooper E Ninio SE Humphries PJ Talmud, Atherosclerosis 2006 189 149 156 10.1016/j.atherosclerosis.2005.12. 009 16438975
45. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. TD Filippatos IF Gazi EN Liberopoulos VG Athyros MS Elisaf AD Tselepis DN Kiortsis, Atherosclerosis 2007 193 428 437 10.1016/j. atherosclerosis.2006.07.010 16911813